TY  - JOUR
A1  - Riquelme, Paloma
A1  - Haarer, Jan
A1  - Kammler, Anja
A1  - Walter, Lisa
A1  - Tomiuk, Stefan
A1  - Ahrens, Norbert
A1  - Wege, Anja K.
A1  - Goecze, Ivan
A1  - Zecher, Daniel
A1  - Banas, Bernhard
A1  - Spang, Rainer
A1  - Fändrich, Fred
A1  - Lutz, Manfred B.
A1  - Sawitzki, Birgit
A1  - Schlitt, Hans J.
A1  - Ochando, Jordi
A1  - Geissler, Edward K.
A1  - Hutchinson, James A.
T1  - TIGIT\(^+\) iTregs elicited by human regulatory macrophages control T cell immunity
JF  - Nature Communications
N2  - Human regulatory macrophages (Mreg) have shown early clinical promise as a cell-based adjunct immunosuppressive therapy in solid organ transplantation. It is hypothesised that recipient CD4(+) T cell responses are actively regulated through direct allorecognition of donor-derived Mregs. Here we show that human Mregs convert allogeneic CD4(+) T cells to IL-10-producing, TIGIT(+) FoxP3(+)-induced regulatory T cells that non-specifically suppress bystander T cells and inhibit dendritic cell maturation. Differentiation of Mreg-induced Tregs relies on multiple non-redundant mechanisms that are not exclusive to interaction of Mregs and T cells, including signals mediated by indoleamine 2,3-dioxygenase, TGF-beta, retinoic acid, Notch and progestagen-associated endometrial protein. Preoperative administration of donor-derived Mregs to living-donor kidney transplant recipients results in an acute increase in circulating TIGIT(+) Tregs. These results suggest a feed-forward mechanism by which Mreg treatment promotes allograft acceptance through rapid induction of direct-pathway Tregs.
KW  - Allotransplantation
KW  - Immunosuppression
KW  - Monocytes and macrophages
KW  - Regulatory T cells
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226321
VL  - 9
IS  - 9
ER  - 
TY  - JOUR
A1  - Aukema, Sietse M.
A1  - Kreuz, Markus
A1  - Kohler, Christian W.
A1  - Rosolowski, Maciej
A1  - Hasenclever, Dirk
A1  - Hummel, Michael
A1  - Küppers, Ralf
A1  - Lenze, Diddo
A1  - Ott, German
A1  - Pott, Christiane
A1  - Richter, Julia
A1  - Rosenwald, Andreas
A1  - Szczepanowski, Monika
A1  - Schwaenen, Carsten
A1  - Stein, Harald
A1  - Trautmann, Heiko
A1  - Wessendorf, Swen
A1  - Trümper, Lorenz
A1  - Loeffler, Markus
A1  - Spang, Rainer
A1  - Kluin, Philip M.
A1  - Klapper, Wolfram
A1  - Siebert, Reiner
T1  - Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma
JF  - Haematologica
N2  - Chromosomal translocations affecting the MYC oncogene are the biological hallmark of Burkitt lymphomas but also occur in a subset of other mature B-cell lymphomas. If accompanied by a chromosomal break targeting the BCL2 and/or BCL6 oncogene these MYC translocation-positive (MYC+) lymphomas are called double-hit lymphomas, otherwise the term single-hit lymphomas is applied. In order to characterize the biological features of these MYC+ lymphomas other than Burkitt lymphoma we explored, after exclusion of molecular Burkitt lymphoma as defined by gene expression profiling, the molecular, pathological and clinical aspects of 80 MYC-translocation-positive lymphomas (31 single-hit, 46 double-hit and 3 MYC+-lymphomas with unknown BCL6 status). Comparison of single-hit and double-hit lymphomas revealed no difference in MYC partner (IG/non-IG), genomic complexity, MYC expression or gene expression profile. Double-hit lymphomas more frequently showed a germinal center B-cell-like gene expression profile and had higher IGH and MYC mutation frequencies. Gene expression profiling revealed 130 differentially expressed genes between BCL6(+)/MYC+ and BCL2(+)/MYC+ double-hit lymphomas. BCL2(+)/MYC+ double-hit lymphomas more frequently showed a germinal center B-like gene expression profile. Analysis of all lymphomas according to MYC partner (IG/non-IG) revealed no substantial differences. In this series of lymphomas, in which immunochemotherapy was administered in only a minority of cases, single-hit and double-hit lymphomas had a similar poor outcome in contrast to the outcome of molecular Burkitt lymphoma and lymphomas without the MYC break. Our data suggest that, after excluding molecular Burkitt lymphoma and pediatric cases, MYC+ lymphomas are biologically quite homogeneous with single-hit and double-hit lymphomas as well as IG-MYC and non-IG-MYC+ lymphomas sharing various molecular characteristics.
KW  - Rituximab plus
KW  - cyclophsophamide
KW  - c-myc
KW  - gene expression
KW  - genomic aberrations
KW  - follicular lymphoma
KW  - prognostic factor
KW  - poor prognosis
KW  - grade 3B
KW  - distinct
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-116882
SN  - 1592-8721
VL  - 99
IS  - 4
ER  -